The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …

The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling
the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Background Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …

… a T distribution, with the mean of the reference population set to 50 and the SD set to 10
units. Based upon the samples required to obtain stable item statistics, Neuro-QOL T scores are …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

… Tanya Simuni has served as a … Simuni has served as a speaker and received an honorarium
from Acadia, IMPAX, Lundbeck, TEVA Pharmaceuticals, and UCB Pharma; Dr Simuni is on …

Objective: To study the safety and efficacy of a cholinesterase inhibitor, donepezil
hydrochloride, for the treatment of dementia in Parkinson’s disease (PD). Methods: This was a …

Importance Diurnal fluctuations of motor and nonmotor symptoms and a high prevalence of
sleep-wake disturbances in Parkinson disease (PD) suggest a role of the circadian system in …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease. Traditionally, attention has focused on the motor symptomatology of PD, but …